Table 2. Effectiveness of the BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines against Covid-19, Hospitalization, and Death, as a Function of Time Elapsed since the First Dose.*.
| Months since First Dose | Covid-19 | Hospitalization | Death | ||||||
|---|---|---|---|---|---|---|---|---|---|
| BNT162b2 | mRNA-1273 | Ad26.COV2.S | BNT162b2 | mRNA-1273 | Ad26.COV2.S | BNT162b2 | mRNA-1273 | Ad26.COV2.S | |
| % (95% CI) | |||||||||
| 1 | 85.5 (85.0–86.0) | 78.0 (77.2–78.8) | 74.8 (72.5–76.9) | 87.7 (85.9–89.3) | 75.2 (72.1–78.0) | 77.7 (68.0–84.5) | 91.6 (88.6–93.8) | 88.3 (83.6–91.7)† | 65.5 (28.5–83.4) |
| 2 | 94.5 (94.1–94.9) | 95.9 (95.5–96.2) | 71.4 (68.3–74.2) | 96.4 (95.1–97.4) | 97.2 (96.1–98.0) | 85.8 (74.9–91.9) | 98.0 (95.5–99.1) | 98.6 (97.3–99.3) | 82.2 (46.3–94.1) |
| 3 | 88.2 (87.5–88.8) | 92.5 (91.9–93.1) | 71.1 (68.2–73.6) | 94.3 (92.5–95.7) | 95.2 (93.4–96.6) | 85.4 (75.7–91.2) | 94.6 (89.7–97.2) | 93.3 (87.7–96.4) | 85.9 (49.3–96.1) |
| 4 | 84.1 (83.4–84.7) | 91.5 (90.9–92.0) | 61.8 (59.3–64.1) | 94.1 (92.6–95.4) | 96.6 (95.3–97.5) | 80.9 (72.7–86.6) | 94.1 (89.5–96.7) | 96.8 (93.1–98.5) | 75.6 (37.7–90.4) |
| 5 | 80.4 (79.8–81.0) | 87.6 (87.1–88.2) | 59.4 (57.2–61.5) | 91.9 (90.4–93.1) | 95.0 (93.7–96.0) | 82.6 (76.0–87.4) | 92.4 (87.7–95.3) | 95.7 (91.9–97.7) | 67.1 (41.8–81.5) |
| 6 | 75.9 (75.1–76.7) | 83.4 (82.7–84.1) | 64.0 (60.3–67.4) | 90.5 (88.8–91.9) | 94.3 (93.1–95.3) | 81.7 (68.6–89.3) | 91.5 (87.6–94.1) | 92.5 (89.2–94.9) | 71.2 (40.8–86.0) |
| 7 | 66.6 (65.2–67.8) | 80.3 (79.3–81.2) | — | 88.7 (86.9–90.3) | 94.1 (92.7–95.2) | — | 90.5 (87.0–93.1) | 95.5 (93.4–96.9) | — |
| 8 | 67.8 (65.9–69.7) | 77.8 (75.9–79.6) | — | 92.4 (89.7–94.4) | 94.9 (92.4–96.6) | — | 95.5 (92.2–97.4) | 96.0 (92.8–97.8) | — |
*
Estimates of vaccine effectiveness and 95% confidence intervals are shown for the two-dose regimens of BNT162b2 and mRNA-1273 and the one-dose regimen of Ad26.COV2.S.
†
The estimate is extrapolated from the estimates at months 0 and 2.